Georgiev Dimiter B, Manassiev Nikolai A
Department of Gynecology, Sheinovo Hospital, Sofia, Bulgaria.
Medscape Womens Health. 2002 Jul-Aug;7(4):1.
The potential effect of hormone replacement therapy (HRT) on the appearance of the breast on screening mammography is of considerable interest and may have important practical implications.
The aim of this study was to evaluate the changes in the mammographic breast density during long-term continuous combined HRT with 2 different preparations.
Nineteen patients were studied. Fifteen were treated with Climodien (Schering, 2 mg estradiol and 2 mg dienogest [E2/dienogest]), and 4 patients were treated with Kliogest (Novo Nordisk, 2 mg estradiol and 1 mg norethisterone acetate [E2/NETA]). All were followed with yearly mammography for 4 years.
Increase in the mammographic density was noted in 3 patients (15.8%). The change was evident after the first year of treatment with no further change during the rest of the study period.
Long-term therapy with continuous combined HRT (E2/dienogest or E2/NETA) increased breast density in 3/19 (15.8%) of the patients. Our results suggest that the effect of these HRT preparations on mammographic density may be less significant than suggested by the results of similarly designed trials evaluating different HRT preparations.
激素替代疗法（HRT）对乳腺钼靶筛查中乳房外观的潜在影响备受关注，且可能具有重要的实际意义。
本研究旨在评估长期连续联合使用两种不同制剂的HRT期间乳腺钼靶密度的变化。
对19名患者进行了研究。15名患者接受了克龄蒙（先灵公司，2毫克雌二醇和2毫克地诺孕素[E2/地诺孕素]）治疗，4名患者接受了诺坤复（诺和诺德公司，2毫克雌二醇和1毫克醋酸炔诺酮[E2/醋酸炔诺酮]）治疗。所有患者均接受了为期4年的每年一次的乳腺钼靶检查。
3名患者（15.8%）的乳腺钼靶密度增加。这种变化在治疗的第一年之后明显，在研究的其余期间没有进一步变化。
长期连续联合使用HRT（E2/地诺孕素或E2/醋酸炔诺酮）治疗使3/19（15.8%）的患者乳腺密度增加。我们的结果表明，这些HRT制剂对乳腺钼靶密度的影响可能不如评估不同HRT制剂的类似设计试验结果所显示的那么显著。
